Literature DB >> 18981253

Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Aiping Qin1, David W Scott, Jennifer A Thompson, Barbara J Mann.   

Abstract

Francisella tularensis, the highly virulent etiologic agent of tularemia, is a low-dose intracellular pathogen that is able to escape from the phagosome and replicate in the cytosol. Although there has been progress in identifying loci involved in the pathogenicity of this organism, analysis of the genome sequence has revealed few obvious virulence factors. We previously reported isolation of an F. tularensis subsp. tularensis strain Schu S4 transposon insertion mutant with a mutation in a predicted hypothetical lipoprotein, FTT1103, that was deficient in intracellular replication in HepG2 cells. In this study, a mutant with a defined nonpolar deletion in FTT1103 was created, and its phenotype, virulence, and vaccine potential were characterized. A phagosomal integrity assay and lysosome-associated membrane protein 1 colocalization revealed that DeltaFTT1103 mutant bacteria were defective in phagosomal escape. FTT1103 mutant bacteria were maximally attenuated in the mouse model; mice survived, without visible signs of illness, challenge by more than 10(10) CFU when the intranasal route was used and challenge by 10(6) CFU when the intraperitoneal, subcutaneous, or intravenous route was used. The FTT1103 mutant bacteria exhibited dissemination defects. Mice that were infected by the intranasal route had low levels of bacteria in their livers and spleens, and these bacteria were cleared by 3 days postinfection. Mutant bacteria inoculated by the subcutaneous route failed to disseminate to the lungs. BALB/c or C57BL/6 mice that were intranasally vaccinated with 10(8) CFU of FTT1103 mutant bacteria were protected against subsequent challenge with wild-type strain Schu S4. These experiments identified the FTT1103 protein as an essential virulence factor and also demonstrated the feasibility of creating defined attenuated vaccines based on a type A strain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981253      PMCID: PMC2612291          DOI: 10.1128/IAI.01113-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  61 in total

Review 1.  DsbA: a protein-folding catalyst contributing to bacterial virulence.

Authors:  J Yu; J S Kroll
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

2.  The dsbA-dsbB disulfide bond formation system of Burkholderia cepacia is involved in the production of protease and alkaline phosphatase, motility, metal resistance, and multi-drug resistance.

Authors:  S Hayashi; M Abe; M Kimoto; S Furukawa; T Nakazawa
Journal:  Microbiol Immunol       Date:  2000       Impact factor: 1.955

3.  Site-directed disulfide cross-linking shows that cleft flexibility in the periplasmic domain is needed for the multidrug efflux pump AcrB of Escherichia coli.

Authors:  Yumiko Takatsuka; Hiroshi Nikaido
Journal:  J Bacteriol       Date:  2007-09-28       Impact factor: 3.490

4.  Francisella tularensis induces cytopathogenicity and apoptosis in murine macrophages via a mechanism that requires intracellular bacterial multiplication.

Authors:  X H Lai; I Golovliov; A Sjöstedt
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.

Authors:  Jiaxin Li; Cheryl Ryder; Manas Mandal; Farzana Ahmed; Parastoo Azadi; D Scott Snyder; Roger D Pechous; Thomas Zahrt; Thomas J Inzana
Journal:  Microbiology       Date:  2007-09       Impact factor: 2.777

6.  Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways.

Authors:  Leah E Cole; Araceli Santiago; Eileen Barry; Tae Jin Kang; Kari Ann Shirey; Zachary J Roberts; Karen L Elkins; Alan S Cross; Stefanie N Vogel
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

7.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

8.  Identification of Francisella tularensis lipoproteins that stimulate the toll-like receptor (TLR) 2/TLR1 heterodimer.

Authors:  Shalini Thakran; Hanfen Li; Christy L Lavine; Mark A Miller; James E Bina; Xiaowen R Bina; Fabio Re
Journal:  J Biol Chem       Date:  2007-12-13       Impact factor: 5.157

Review 9.  Animal models of Francisella tularensis infection.

Authors:  C Rick Lyons; Terry H Wu
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

10.  Toll-like receptor 2 controls the gamma interferon response to Francisella tularensis by mouse liver lymphocytes.

Authors:  Kee-Jong Hong; Jason R Wickstrum; Hung-Wen Yeh; Michael J Parmely
Journal:  Infect Immun       Date:  2007-09-04       Impact factor: 3.441

View more
  62 in total

1.  A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.

Authors:  Qingmei Jia; Bai-Yu Lee; Richard Bowen; Barbara Jane Dillon; Susan M Som; Marcus A Horwitz
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  Multimethodological approach to identification of glycoproteins from the proteome of Francisella tularensis, an intracellular microorganism.

Authors:  Lucie Balonova; Lenka Hernychova; Benjamin F Mann; Marek Link; Zuzana Bilkova; Milos V Novotny; Jiri Stulik
Journal:  J Proteome Res       Date:  2010-04-05       Impact factor: 4.466

Review 3.  Life on the inside: the intracellular lifestyle of cytosolic bacteria.

Authors:  Katrina Ray; Benoit Marteyn; Philippe J Sansonetti; Christoph M Tang
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633

4.  Directed screen of Francisella novicida virulence determinants using Drosophila melanogaster.

Authors:  Monika K Ahlund; Patrik Rydén; Anders Sjöstedt; Svenja Stöven
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

5.  A Francisella tularensis locus required for spermine responsiveness is necessary for virulence.

Authors:  Brian C Russo; Joseph Horzempa; Dawn M O'Dee; Deanna M Schmitt; Matthew J Brown; Paul E Carlson; Ramnik J Xavier; Gerard J Nau
Journal:  Infect Immun       Date:  2011-06-13       Impact factor: 3.441

6.  Molecular complexity orchestrates modulation of phagosome biogenesis and escape to the cytosol of macrophages by Francisella tularensis.

Authors:  Rexford Asare; Yousef Abu Kwaik
Journal:  Environ Microbiol       Date:  2010-05-07       Impact factor: 5.491

7.  FipB, an essential virulence factor of Francisella tularensis subsp. tularensis, has dual roles in disulfide bond formation.

Authors:  Aiping Qin; Yan Zhang; Melinda E Clark; Meaghan M Rabideau; Luis R Millan Barea; Barbara J Mann
Journal:  J Bacteriol       Date:  2014-08-04       Impact factor: 3.490

Review 8.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

9.  Francisella tularensis type B ΔdsbA mutant protects against type A strain and induces strong inflammatory cytokine and Th1-like antibody response in vivo.

Authors:  Adela Straskova; Petra Spidlova; Sherry Mou; Patricia Worsham; Daniela Putzova; Ivona Pavkova; Jiri Stulik
Journal:  Pathog Dis       Date:  2015-08-06       Impact factor: 3.166

Review 10.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.